1-20 of 30
neoplasm, residual
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial

Rachel J. Mitchell, Amy A. Kirkwood, Emilio Barretta, Laura Clifton-Hadley, Emma Lawrie, SooWah Lee, Daniel Leongamornlert, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Elli Papaemmanuil, Bela Patel, Pip Patrick, Clare J. Rowntree, Nahid Zareian, Krisztina Zuborne Alapi, Anthony V. Moorman, Adele K. Fielding
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3322–3332.
https://doi.org/10.1182/bloodadvances.2021004430
Published: 2021
Includes: Supplemental data
Journal Articles

Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial

Clinical Trials & Observations
Etan Orgel, Celia Framson, Rubi Buxton, Jiyoon Kim, Gang Li, Jonathan Tucci, David R. Freyer, Weili Sun, Matthew J. Oberley, Christina Dieli-Conwright, Steven D. Mittelman
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1853–1861.
https://doi.org/10.1182/bloodadvances.2020004018
Published: 2021
Includes: Supplemental data
Journal Articles

Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol

Clinical Trials & Observations
Akhil Rajendra, Hasmukh Jain, V. N. Avinash Bonda, Lingaraj Nayak, Prashant Tembhare, Dhanlaxmi Shetty, Jayashree Thorat, Hemani Jain, Papagudi Ganesan Subramanian, Nikhil Patkar, Gaurav Chatterjee, Navin Khattry, Anant Gokarn, Sachin Punatar, Smruti Mokal, Bhausaheb Bagal, Manju Sengar
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1178–1193.
https://doi.org/10.1182/bloodadvances.2020003526
Published: 2021
Includes: Supplemental data
Journal Articles

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Clinical Trials & Observations
Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J. Costa, Yana Lutska, Padma Bobba, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas S. Lin, Paul G. Richardson
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1092–1096.
https://doi.org/10.1182/bloodadvances.2020003642
Published: 2021
Journal Articles

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma

Clinical Trials & Observations
Wen-Kai Weng, Sally Arai, Andrew Rezvani, Laura Johnston, Robert Lowsky, David Miklos, Judith Shizuru, Lori Muffly, Everett Meyer, Robert S. Negrin, Erica Wang, Timothy Almazan, Lynn Million, Michael Khodadoust, Shufeng Li, Richard T. Hoppe, Youn H. Kim
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4474–4482.
https://doi.org/10.1182/bloodadvances.2020001627
Published: 2020
Journal Articles

CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia

Anthony Quagliano, Anilkumar Gopalakrishnapillai, E. Anders Kolb, Sonali P. Barwe
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4393–4405.
https://doi.org/10.1182/bloodadvances.2020001592
Published: 2020
Includes: Supplemental data
Journal Articles

Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults

Clinical Trials & Observations
Heather J. Symons, Marianna Zahurak, Yilin Cao, Allen Chen, Kenneth Cooke, Christopher Gamper, Orly Klein, Nicolas Llosa, Elias T. Zambidis, Richard Ambinder, Javier Bolaños-Meade, Ivan Borrello, Robert Brodsky, Amy DeZern, Ivana Gojo, Margaret Showel, Lode Swinnen, B. Douglas Smith, Leo Luznik, Richard J. Jones, Ephraim J. Fuchs
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3913–3925.
https://doi.org/10.1182/bloodadvances.2020001648
Published: 2020
Includes: Supplemental data
Journal Articles

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Clinical Trials & Observations
Marie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, Pierre Feugier, Hervé Maisonneuve, Rene-Olivier Casasnovas, François Lemonnier, Gian Matteo Pica, Roch Houot, Loic Ysebaert, Hervé Tilly, Jean-Claude Eisenmann, Steven Le Gouill, Vincent Ribrag, Pascal Godmer, Sylvie Glaisner, Guillaume Cartron, Luc Xerri, Gilles André Salles, Thierry Fest, Franck Morschhauser
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3217–3223.
https://doi.org/10.1182/bloodadvances.2020001955
Published: 2020
Includes: Supplemental data
Journal Articles

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission

Clinical Trials & Observations
Philippe Rousselot, Clémence Loiseau, Marc Delord, Jean Michel Cayuela, Marc Spentchian
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3034–3040.
https://doi.org/10.1182/bloodadvances.2020001772
Published: 2020
Includes: Supplemental data
Journal Articles

Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis

Clinical Trials & Observations
Andrew Staron, Eric J. Burks, John C. Lee, Shayna Sarosiek, J. Mark Sloan, Vaishali Sanchorawala
Journal: Blood Advances
Blood Adv (2020) 4 (5): 880–884.
https://doi.org/10.1182/bloodadvances.2019001331
Published: 2020
Journal Articles

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Clinical Trials & Observations
Reid W. Merryman, Natasha Edwin, Robert Redd, Jad Bsat, Matthew Chase, Ann LaCasce, Arnold Freedman, Caron Jacobson, David Fisher, Samuel Ng, Jennifer Crombie, Austin Kim, Oreofe Odejide, Matthew S. Davids, Jennifer R. Brown, Heather Jacene, Amanda Cashen, Nancy L. Bartlett, Neha Mehta-Shah, Armin Ghobadi, Brad Kahl, Robin Joyce, Philippe Armand, Eric Jacobsen
Journal: Blood Advances
Blood Adv (2020) 4 (5): 858–867.
https://doi.org/10.1182/bloodadvances.2019001355
Published: 2020
Includes: Supplemental data
Journal Articles

Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity

Clinical Trials & Observations
Franziska Schramm, Udo zur Stadt, Martin Zimmermann, Norbert Jorch, Arnulf Pekrun, Arndt Borkhardt, Thomas Imschweiler, Holger Christiansen, Jörg Faber, Irene Schmid, Tobias Feuchtinger, Gerhard Beron, Monique L. den Boer, Rob Pieters, Martin A. Horstmann, Gritta E. Janka-Schaub, Gabriele Escherich
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3688–3699.
https://doi.org/10.1182/bloodadvances.2019000576
Published: 2019
Includes: Supplemental data
Journal Articles

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Clinical Trials & Observations
Nicola Gökbuget, Hagop M. Kantarjian, Monika Brüggemann, Anthony S. Stein, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Leonard Heffner, Françoise Rigal-Huguet, Mark Litzow, Susan O’Brien, Gerhard Zugmaier, Shan Gao, Dirk Nagorsen, Stephen J. Forman, Max S. Topp
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3033–3037.
https://doi.org/10.1182/bloodadvances.2019000457
Published: 2019
Includes: Supplemental data
Journal Articles

Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval

Adam Yuh Lin, Shira Naomi Dinner
Journal: Blood Advances
Blood Adv (2019) 3 (19): 2905–2910.
https://doi.org/10.1182/bloodadvances.2019000507
Published: 2019
Journal Articles

Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition

Clinical Trials & Observations
Matthew J. Pianko, Sean M. Devlin, Eric R. Littmann, Aisara Chansakul, Donna Mastey, Meghan Salcedo, Emily Fontana, Lilan Ling, Elizabet Tavitian, John B. Slingerland, Ann E. Slingerland, Annelie Clurman, Antonio L. C. Gomes, Ying Taur, Eric G. Pamer, Jonathan U. Peled, Marcel R. M. van den Brink, Ola Landgren, Alexander M. Lesokhin
Journal: Blood Advances
Blood Adv (2019) 3 (13): 2040–2044.
https://doi.org/10.1182/bloodadvances.2019032276
Published: 2019
Includes: Supplemental data
Journal Articles

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

Clinical Trials & Observations
Amy K. Keating, Nathan Gossai, Christine L. Phillips, Kelly Maloney, Kristen Campbell, Andrew Doan, Deepa Bhojwani, Michael J. Burke, Michael R. Verneris
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1926–1929.
https://doi.org/10.1182/bloodadvances.2018025726
Published: 2019
Journal Articles

CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study

Clinical Trials & Observations
M. O’Dwyer, R. Henderson, S. D. Naicker, M. R. Cahill, P. Murphy, V. Mykytiv, J. Quinn, C. McEllistrim, J. Krawczyk, J. Walsh, E. Lenihan, T. Kenny, A. Hernando, G. Hirakata, I. Parker, E. Kinsella, G. Gannon, A. Natoni, K. Lynch, A. E. Ryan
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1815–1825.
https://doi.org/10.1182/bloodadvances.2019000010
Published: 2019
Includes: Supplemental data
Journal Articles

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL

Clinical Trials & Observations
Lina Hamadeh, Amir Enshaei, Claire Schwab, Cristina N. Alonso, Andishe Attarbaschi, Gisela Barbany, Monique L. den Boer, Judith M. Boer, Marcin Braun, Luciano Dalla Pozza, Sarah Elitzur, Mariana Emerenciano, Larisa Fechina, Maria Sara Felice, Eva Fronkova, Irén Haltrich, Mats M. Heyman, Keizo Horibe, Toshihiko Imamura, Marta Jeison, Gábor Kovács, Roland P. Kuiper, Wojciech Mlynarski, Karin Nebral, Ingegerd Ivanov Öfverholm, Agata Pastorczak, Rob Pieters, Henriett Piko, Maria S. Pombo-de-Oliveira, Patricia Rubio, Sabine Strehl, Jan Stary, Rosemary Sutton, Jan Trka, Grigory Tsaur, Nicola Venn, Ajay Vora, Mio Yano, Christine J. Harrison, Anthony V. Moorman
Journal: Blood Advances
Blood Adv (2019) 3 (2): 148–157.
https://doi.org/10.1182/bloodadvances.2018025718
Published: 2019
Includes: Supplemental data
Journal Articles

IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice

Yimin Shi, Lillia Dincheva-Vogel, Charles E. Ayemoba, Jeffrey P. Fung, Cristina Bergamaschi, George N. Pavlakis, Farzin Farzaneh, Karin M. L. Gaensler
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3177–3192.
https://doi.org/10.1182/bloodadvances.2018019026
Published: 2018
Includes: Supplemental data
Journal Articles

NPM1 mutated AML can relapse with wild-type NPM1 : persistent clonal hematopoiesis can drive relapse

Clinical Trials & Observations
Alexander Höllein, Manja Meggendorfer, Frank Dicker, Sabine Jeromin, Niroshan Nadarajah, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3118–3125.
https://doi.org/10.1182/bloodadvances.2018023432
Published: 2018